Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer
Ist Teil von
Clinical cancer research, 2005-12, Vol.11 (23), p.8326-8331
Ort / Verlag
United States: American Association for Cancer Research
Erscheinungsjahr
2005
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
Purpose: The forkhead box transcription factor FoxP3 is specifically expressed in T cells with regulatory properties (Treg). Recently,
high numbers of Treg were described to be associated with poor survival in different malignancies. The aim of the presented
study was determine the prognostic effect of FoxP3 mRNA expression (reflecting the tissue content of Treg) in ovarian carcinoma
and its relation with cytokines, such as IFN-γ.
Experimental Design: Total RNA was isolated from 99 ovarian carcinoma and from 14 healthy ovarian biopsies. Real-time PCR for FoxP3 was done and
correlated with IFN-γ-, CD3-, IRF-1-, SOCS-1-, HER-2-, and iNOS expression as well as patients' outcome. The mRNA data was
corroborated by FoxP3 immunohistochemistry.
Results: Quantitation of FoxP3 expression identified a patient subgroup (>81th percentile), which is characterized by a significantly
worse prognosis in terms of overall survival (27.8 versus 77.3 months, P = 0.0034) and progression-free survival (18 versus 57.5 months; P = 0.0041). FoxP3 expression correlated with IFN-γ, IRF-1, and CD3 expression. High FoxP3 expression represents an independent
prognostic factor for overall survival ( P = 0.004) and progression-free survival ( P = 0.004).
Conclusions: High expression levels of FoxP3 might represent a surrogate marker for an immunosuppressive milieu contributing to tumor
immune escape. Strategies selectively depleting Treg might improve the antitumor activity of endogenously arising tumor-reactive
T cells and immunotherapies using vaccines or antibodies.